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 Inhibition of the Tyrosine Phosphatase 
SHP-2 Suppresses Angiogenesis in vitro 
and in vivo 
 Hanna Mannell a    Nicole Hellwig a    Torsten Gloe a    Christian Plank c    
Hae-Young Sohn b    Leopold Groesser a    Barbara Walzog a    Ulrich Pohl a    
Florian Krötz a, b 
 Institute of  a  Physiology and  b  Cardiology, Medical Policlinic, Ludwig Maximilians University, and
 c  Department of Experimental Oncology and Therapeutic Research, Technical University,  Munich , Germany 
gest that SHP-2 regulates endothelial cell survival through 
PI3-K-Akt and mitogen-activated protein kinase pathways 
thereby strongly affecting new vessel formation. Thus, SHP-
2 exhibits a pivotal role in angiogenesis and may represent 
an interesting target for therapeutic approaches controlling 
vessel growth.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 The Src homology 2 domain containing tyrosine phos-
phatase 2, SHP-2 (also called SH-PTP2, SH-PTP3, PT-
P2C, PTP1D or Syp), is ubiquitously expressed and pos-
sibly also functions as an adaptor protein  [1–4] . During 
the development of hematopoietic cells, it maintains the 
critical balance between apoptosis, proliferation and dif-
ferentiation  [5–7] . In endothelial cells, SHP-2 interacts 
with adhesion molecules, such as PECAM-1 and VE-cad-
herin, thereby participating in mechanotransduction 
and cell motility  [8–10] . Mobilization of endothelial cells 
is a prerequisite for angiogenesis, during which the pre-
vention of endothelial apoptosis or anoikis (programmed 
cell death due to detachment from the extracellular ma-
trix)  [11–13] is of major importance in order to enable the 
formation of new vessels from already existing ones.
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 Abstract 
 Endothelial cell survival is indispensable to maintain endo-
thelial integrity and initiate new vessel formation. We inves-
tigated the role of SHP-2 in endothelial cell survival and an-
giogenesis in vitro as well as in vivo. SHP-2 function in 
cultured human umbilical vein and human dermal microvas-
cular endothelial cells was inhibited by either silencing the 
protein expression with antisense-oligodesoxynucleotides 
or treatment with a pharmacological inhibitor (PtpI IV). SHP-
2 inhibition impaired capillary-like structure formation (p  ! 
0.01; n = 8) in vitro  as well as new vessel growth ex vivo  (p  ! 
0.05; n = 10) and in vivo in the chicken chorioallantoic mem-
brane (p  ! 0.01, n = 4) .  Additionally, SHP-2 knock-down ab-
rogated fibroblast growth factor 2 (FGF-2)-dependent endo-
thelial proliferation measured by MTT reduction (p  ! 0.01; 
n = 12). The inhibitory effect of SHP-2 knock-down on vessel 
growth was mediated by increased endothelial apoptosis 
(annexin V staining, p  ! 0.05, n = 9), which was associated 
with reduced FGF-2-induced phosphorylation of phosphati-
dylinositol 3-kinase (PI3-K), Akt and extracellular regulated 
kinase 1/2 (ERK1/2) and involved diminished ERK1/2 phos-
phorylation after PI3-K inhibition (n = 3). These results sug-
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 The outstanding role of fibroblast growth factor 2 
(FGF-2) in angiogenesis  [11, 14, 15] is reflected by its high 
local concentrations during wound healing  [16, 17] . FGF-
2 has also been suggested to facilitate the angiogenic 
growth response of endothelial cells during ischemia  [18] . 
Furthermore, apart from promoting endothelial prolif-
eration and migration, FGF-2 is one of the strongest me-
diators of endothelial cell survival  [11, 15] and induces 
tube-like structure formation  [14, 17, 18] . A potential role 
of SHP-2 in FGF-2-dependent endothelial cell signaling, 
influencing the FGF-2-dependent angiogenic response, 
has not yet been explored. In addition, it is unclear wheth-
er SHP-2 is involved in endothelial cell survival and new 
vessel formation and thus could be important for angio-
genesis in vivo.
 Therefore, we investigated whether SHP-2 is involved 
in human endothelial cell survival, tube-like structure 
formation in vitro, vessel sprouting ex vivo and whether 
a functional SHP-2 is necessary for the formation of new 
vessels in vivo. Finally, we explored if SHP-2 influences 
the FGF-2-dependent activation of the anti-apoptotic sig-
naling pathways phosphatidylinositol 3-kinase (PI3-K)/
Akt and mitogen-activated protein kinase (MAPK) in en-
dothelial cells.
 Materials and Methods 
 Chemicals 
 Monoclonal SHP-2 antibody, polyclonal phospho-Akt 1/2/3 
antibody and actin antibody were from Santa Cruz Biotechnology 
(Heidelberg, Germany). Monoclonal phospho-42/44 antibody 
was from Cell Signaling (Frankfurt am Main, Germany). Mono-
clonal phosphotyrosine antibody (clone 4G10) was from Upstate 
(Hamburg, Germany) and monoclonal GAPDH antibody was 
from Chemicon (Chandlers Ford, UK). Horseradish peroxidase-
conjugated antibodies and the pharmacological SHP-2 inhibitor 
(PtpI IV) were from Calbiochem (Darmstadt, Germany). FGF-2 
was purchased from Tebu-bio (Offenbach, Germany). All other 
chemicals were from Sigma-Aldrich (Taufkirchen, Germany).
 Cell Lines and Cell Culture 
 Human umbilical vein endothelial cells (HUVEC) were iso-
lated and cultured as described previously  [19] . Human dermal 
microvascular endothelial cells (HMEC) were provided by Ades 
et al.  [20] and cultured in M199 media supplemented with 10% 
FCS, 10% endothelial growth media (PromoCell, Heidelberg, 
Germany) and 1% penicillin/streptomycin.
 Antisense-Oligodesoxynucleotide Transfer 
 Endothelial SHP-2 protein was knocked down by phosphoro-
thioate-modified oligodesoxynucleotide (ODN) transfection us-
ing the previously described magnetofection technique  [21–23] . 
Control transfections were performed using an ODN with a ran-
dom sequence not aligning to any human mRNA (Rdm-ODN). 
Oligonucleotide sequences were as follows: SHP-2 antisense
(AS)-ODN: 5  -ctccgcgatgtcatgttcct-3  , Rdm-ODN: 5  -cccttatttac-
tactttcgc-3  (both from MWG Biotech, Ebersberg, Germany). To 
control for efficient transfection, Cy-3 fluorescence-labeled ODN 
were transfected and sufficient efficiency was controlled for by 
flow-cytometric analysis ( 1 80%) as described  [21] .
 Cell Extracts for Immunoblotting and Western Blot Analysis 
 Protein lysates were prepared and protein content quantified 
according to a previous method  [24] . Lysates were subjected to 
Western blot analysis as shown  [24] .
 MTT Assay 
 Cell proliferation and cell survival of HMEC was measured by 
the reduction of methylthiazoletetrazolium, MTT (0.5 mg/ml), as 
described by Mosmann et al.  [25] with minor modifications, as 
well as by measuring protein concentration with the BCA kit 
(Pierce, Bonn, Germany) according to the supplier’s protocol.
 Cell Viability and Apoptosis Measurements 
 Cell cycle states of HUVEC were assessed by flow-cytometric 
measurement of propidium iodide-stained DNA according to 
Crompton et al.  [26] , with minor modifications, to analyze cell vi-
ability. To assess the amount of intact, yet apoptotic cells, an an-
nexin V/propidium iodide assay was performed whereby double 
staining against annexin V together with propidium iodide sepa-
rates cells currently undergoing apoptosis, but which are not ne-
crotic, from cells that have died of necrosis. The assay was per-
formed according to the manufacturer’s instructions (Annexin V 
Apoptosis detection kit 1, BD Biosciences, Heidelberg, Germany) 
and annexin V positive but propidium iodide negative cells were 
detected by flow cytometry.  Cell viability was assessed by trypan 
blue exclusion. Cells were detached non-enzymatically from the cell 
dish, diluted 1: 1 in PBS and 0.2% trypan blue, incubated for 2 min 
and subsequently counted with fast-read counting chambers (Bio-
sigma, Cona, Italy). Cells stained blue were counted as non-viable.
 Immunoprecipitation of p85 
 Immunoprecipitations were performed using   MACS Protein 
G MicroBeads and MACS separation columns from Miltenyi Bio-
tec (Bergisch Gladbach, Germany) according to the manufactur-
er’s protocol. The activity of PI3-K was assessed by immunoblot-
ting against phosphotyrosine.
 Activity Assays 
 For extracellular regulated kinase 1/2 (ERK1/2) and Akt activ-
ity, cells were treated with 10 ng/ml FGF-2 for 10 min, lysed and the 
lysate submitted to Western blotting as described above. Mem-
branes were incubated with the respective phospho-antibodies. An 
anti-GAPDH antibody was used to ensure equal protein loading.
 Capillary-Like Structure Assay 
 Confluent HUVEC were treated with PtpI IV (2   M )  [27] or 
DMSO (sham group) for 6 h, SHP-2 AS-ODN or Rdm-ODN 24 h 
prior to trypsination. The cells were then seeded onto a 24-well 
plate filled with growth factor-reduced Matrigel (BD Biosciences, 
Erembodegem, Belgium) and left to form capillary-like structures 
overnight in growth factor-rich medium. Pictures were taken 
with an LSM 410 microscope, and the capillary-like structures in 
each sector were counted.
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 Aortic Ring Sprouting Assay 
 Adult Black 6 mice were euthanized with an overdose of so-
dium pentobarbital (Narcoren TM ; Merial, Hallbergmoos, Ger-
many) and aortae were dissected. After rinsing with Tutofusin 
Voll-E  (Baxter, Unterschleissheim, Germany), aortae were cut 
into rings and embedded in growth factor-reduced Matrigel. 
They were then treated with and kept in either 2   M PtpI IV or 
DMSO (sham group) in growth media. The aortic rings were left 
for 96 h. Pictures were taken with an LSM 410 microscope. To 
measure angiogenesis, the bifurcations of the new vessels were 
counted manually.
 Chick Chorioallantoic Membrane Assay 
 The effect of SHP-2 inhibition on angiogenesis in vivo was in-
vestigated on the chorioallantoic membrane (CAM) of 10-day-old 
chicken embryos, as previously described by Brooks et al.  [28] , 
with minor modifications. Chicken embryos were candled to vi-
sualize the existing blood vessels of the CAM and a spot where no 
vessels were growing was chosen. At this spot, the CAM was next 
separated from the shell generating a false air sac above which a 
small window was cut out. A filter disc soaked in FGF-2/VEGF-A 
(both 50 ng/ml) and DMSO (sham solution), in FGF-2/VEGF-A 
(50 ng/ml) and PtpI IV (2   M ) or in DMSO (sham solution) was 
carefully placed on top of the CAM. The window was sealed with 
adhesive tape and the embryos were left in a humidified incubator 
for 3 days. The sham solution and PtpI IV were applied every day 
to the filter discs. Before removal of the filter disc and surround-
ing CAM tissue, the CAM was fixed in formalin (3.7%). The re-
moved filter and CAM tissue were washed in PBS before photos 
of the CAM were taken with an AxioCam microscope (Zeiss, 
Jena, Germany). As an index of angiogenesis, the number of 
branching points (bifurcations) of the vessels formed per visual 
field was counted.
 Statistical Analysis 
 Data were analysed using Student’s t test, one-way ANOVA or 
a rank sum test, as appropriate. All data are presented as means 
 8 SEM. Results were considered significant at an error probabil-
ity level of p  ! 0.05.
 Results 
 SHP-2 Protein Knock-Down Decreases Endothelial 
Cell MTT Reduction 
 Previous studies using AS-ODN combined with mag-
netofection in HUVEC have shown a transfection efficien-
cy of  1 80% compared to conventional transfection  [21] . 
Compared to Rdm-ODN treatment, SHP-2 AS-ODN re-
sulted in a marked decrease in SHP-2 protein content in 
endothelial cells (HUVEC and HMEC) already after 6 h, 
and was still seen 24 h following magnetofection ( fig. 1 a, 
all n = 3). Therefore, the following experiments were per-
formed during or 6–24 h following transfection. A down-
regulation of SHP-2 protein expression precluded the
FGF-2-enhanced MTT reduction, a substrate used to as-
sess the amount of viable cells and cellular proliferation. 
Whereas FGF-2 stimulation of Rdm-ODN-treated cells re-
sulted in a significant increase in MTT reduction com-
pared to non-stimulated cells (p  ! 0.05; n = 9, HMEC, 
 fig. 1 b) and thus proliferation of endothelial cells, SHP-2 
AS-ODN treatment abolished this effect by 41  8 15% (24 h 
after stimulation, p  ! 0.01; n = 12, HMEC,  fig. 1 b) thereby 
reaching values below the starting point (t = 0 h), indicat-
ing a reduction in cell number. To verify these data, HMEC 
protein concentration was measured after ODN treatment 
confirming the previous results, as SHP-2 knock-down fol-
lowed by FGF-2 stimulation reduced the protein content by 
62% ( 8 10% 48 h after stimulation with FGF-2, p  ! 0.01;
n = 9,  fig. 1 c) compared to Rdm-ODN treatment (n = 6).
 Downregulation of SHP-2 Protein Expression Affects 
Endothelial Cell Viability and Induces Apoptosis 
 To investigate if the decreased MTT reduction follow-
ing SHP-2 knock-down was due to apoptosis, HUVEC 
DNA was stained with propidium iodide, and the amount 
of cells with lower amounts of DNA than a cell situated 
in the G0 stage of the cell cycle (SubG0) was detected. As 
these cells contain less DNA than a resting cell, due to 
apoptosis-induced DNA fragmentation, this fraction was 
measured as an index of apoptosis. Six hours after trans-
fection, SHP-2 AS-ODN treatment slightly increased the 
amount of cells in SubG0 compared to Rdm-ODN-trans-
fected cells. Twenty-four hours following transfection, 
this difference reached significance (25  8 5% of all cells 
in SubG0 with SHP-2 AS-ODN in comparison to 10  8 
0.8% with Rdm-ODN,  fig. 2 , p  ! 0.01; n = 6, HUVEC). To 
confirm SHP-2 involvement in endothelial apoptosis, 
cells were stained against the proapoptotic marker an-
nexin V. Following SHP-2 knock-down, there was a sig-
nificant increase in annexin V-positive cells compared to 
Rdm-ODN (23  8 7% 6 h after transfection, p  ! 0.05, n = 
8, HUVEC;  fig. 2 b).
 Inhibition of SHP-2 Impairs the Ability of Endothelial 
Cells to Form Capillary-Like Structures in vitro and 
Negatively Affects Vessel Sprouting in vivo 
 To investigate whether the effects seen after SHP-2 
 deprivation have functional consequences on vessel for-
mation, we firstly performed Matrigel assays. Inhibition 
of SHP-2 with AS-ODN in HUVEC showed a 45  8 13% 
(3  8 0.8 capillary structures/mm 2 , p  ! 0.01, n = 8,
HUVEC,  fig. 3 d, e) reduction in the number of endothe-
lium-dependent capillary-like structures, as they de-
tached themselves from the matrix (dark dots) and the 
capillary structures were incomplete compared to Rdm-
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ODN-treated cells (7  8 0.7 capillary structures/mm 2 , 
 fig. 3 b, e). In addition, treatment with the pharmacologi-
cal SHP-2 inhibitor also reduced the number of capillary-
like structures by 55  8 16% (4  8 1.6 capillary structures/
mm 2 , p  ! 0.05; n = 3, HUVEC,  fig. 3 c, e) compared to 
sham treatment (DMSO diluted v/v to the same extent as 
PtpI IV; 9  8 0.5 capillary structures/mm 2 ,  fig. 3 a, e).
 To further investigate if SHP-2 inhibition directly in-
fluences angiogenesis, new vessel sprouting from isolated 
mouse aortae was assessed in Matrigel. As seen in  fig-
ure 3 f and  3 g, treatment with PtpI IV impaired vessel for-
mation in these experiments. The number of bifurcations 
of the newly formed vessels was remarkably reduced upon 
SHP-2 inhibition (27  8 7 bifurcations/aortic ring, p  ! 
0.05; n = 10,  fig. 3 g, h) in comparison to sham-treated 
aortic rings (59  8 11 bifurcations/aortic ring, n = 8, 
 fig. 3 f, h).
 These findings were confirmed in vivo, using the 
chicken CAM assay. Treatment of the CAM with FGF-2 
and VEGF-A (both 50 ng/ml), to induce a strong angio-
genic response, led to a marked increase in vessel growth 
(639  8 44 bifurcations/visual field, n = 4,  fig. 3 i, k) com-
pared to sham treatment (310  8 29 bifurcations/visual 
field; p  ! 0.01, n = 5,  fig. 3 i, j). Application of PtpI IV, how-
ever, drastically reduced this angiogenic effect (334  8 72 
bifurcations/visual field; p  ! 0.01; n = 4,  fig. 3 i, l). To rule 
out the possibility of the PtpI IV to be cytotoxic and 
therefore contribute to the observed effects, we performed 
a trypan blue exclusion assay with cells treated with PtpI 
IV and DMSO (sham). As seen in  figure 3 m, there was no 
increase in trypan blue-positive cells at any time com-
pared to sham treatment (n = 7). This confirms that the 
effects seen after SHP-2 inhibition are indeed specific 
and not due to cytotoxicity from the solvent.
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 Fig. 1. Knock-down of SHP-2 protein expression and FGF-2 proliferation following 
SHP-2 inhibition.  a SHP-2 was successfully knocked down by SHP-2 AS-ODN trans-
fection combined with magnetofection in both HUVEC ( * * p  ! 0.01, n = 3) and HMEC 
( * p  ! 0.05;  * * p  ! 0.01, both n = 3). Immunoblots show protein expression 6 and
24 h following magnetofection. As a loading control (LCTRL), actin staining was 
performed.  b FGF-2 (10 ng/ml) enhanced endothelial cell proliferation (Rdm-ODN 
+ FGF-2), as assessed by MTT reduction of HMEC compared to non-stimulated cells 
(Rdm-ODN,  * * * p  ! 0.05; n = 9, 48 h after stimulation), whereas FGF-2 stimulation 
was non-effective when SHP-2 was knocked down (SHP-2 AS-ODN + FGF-2,  * * p  ! 
0.01; n = 12, HMEC). Data are normalized to the proliferative response at first mea-
surement (before stimulation, t = 0 h), which is set to 0%.  c SHP-2 knock-down also 
led to a reduction in protein concentration (SHP-2 AS-ODN + FGF-2,  * * p  ! 0.01;
n = 9, HMEC, 48 h after stimulation) compared to Rdm-ODN treatment (Rdm-ODN 
+ FGF-2, n = 6). Data are normalized to the protein content at first measurement (be-
fore stimulation, t = 0 h).  * p  ! 0.05, n = 9, Rdm-ODN vs. Rdm-ODN + FGF-2. 
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 SHP-2 Regulates FGF-2-Dependent Endothelial 
Angiogenic Signaling Pathways 
 To investigate the mechanisms underlying SHP-2-de-
pendent inhibition of endothelial angiogenesis, we tested 
whether SHP-2 affected activation of the PI3-K-Akt path-
way, a prominent regulator of endothelial cell survival 
and angiogenesis  [15, 29] . Whereas tyrosine phosphory-
lation of the p85 subunit was enhanced upon stimulation 
with FGF-2 (n = 3), indicating an activation of PI3-K, it 
decreased upon AS-ODN treatment in comparison to 
Rdm-ODN ( fig. 4 a, n = 3, HMEC) as well as after applica-
tion of PtpI IV ( fig. 4 b, n = 4, HMEC). Furthermore, 
when detecting the phosphorylation of Akt, the down-
stream target of PI3-K, a strong enhancement was seen 
after FGF-2 stimulation (n = 3), whereas inhibition of 
SHP-2 led to diminished Akt phosphorylation ( fig. 4 c,
n = 4, HMEC).
 Secondly, we investigated the influence of SHP-2 on 
endothelial MAPK pathway activation, another eminent 
regulator of angiogenesis  [30] and a promoter of endothe-
lial cell survival. FGF-2 induced strong phosphorylation 
of ERK1/2, as revealed by immunoblotting against phos-
pho-ERK1/2. This was decreased when inhibiting SHP-2 
by SHP-2 AS-ODN (n = 5, HMEC,  fig. 5 a). To ensure the 
specificity of SHP-2 involvement, cells were treated with 
1   M phorbol 12-myristate-13-acetate (PMA), a direct 
stimulator of protein kinase C, which has been shown to 
activate ERK1/2 independently of SHP-2  [38] . This re-
sulted in robust activation of ERK1/2, which, in contrast 
to FGF-2-dependent ERK1/2 activation, was independent 
of SHP-2, as SHP-2 AS-ODN had no effect in these ex-
periments (n = 4, HMEC,  fig. 5 b). To elucidate if PI3-K 
could also be an upstream regulator of the MAPK path-
way and thus targeted by SHP-2 in these experiments, 
PI3-K was next inhibited using wortmannin (10 n M ) be-
fore stimulation with FGF-2. This also led to a decrease 
in ERK1/2 phosphorylation regardless of FGF-2 stimula-
tion (both n = 3, HMEC,  fig. 5 c).
 Discussion 
 Our findings highlight the potential importance of 
endothelial Src homology 2-containing tyrosine phos-
phatase SHP-2 for the formation of new blood vessels and 
shed light on the role of SHP-2 in angiogenic FGF-2-de-
pendent endothelial cell signaling. Our data suggest that 
SHP-2 is substantial for new vessel formation in vivo, a 
crucial event for revascularization of ischemic tissue. We 
show that this involves SHP-2-dependent prevention of 
apoptosis of endothelial cells. Finally, our results high-
light the mechanisms by which SHP-2 plays a pivotal role 
in angiogenic factor-dependent endothelial activation, as 
SHP-2 regulates the MAPK and Akt pathways upon FGF-
2 stimulation, which are critical for cell survival and pro-
liferation through PI3-K.
 In this study in endothelial cells, cellular proliferation 
observed upon FGF-2 stimulation was completely abol-
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 Fig. 2. SHP-2 inhibition increases the 
amount of cells in SubG0 and annexin V 
binding. DNA content was analyzed by 
propidium iodide staining and apoptosis 
was assessed by measurement of annexin 
V binding followed by FACS analysis.  a A 
 significant increase in  the SubG0 fraction 
( * * p  ! 0.01; n = 6, HUVEC, 24 h after 
transfection) was observed after SHP-2 
AS-ODN treatment in comparison to 
Rdm-ODN treatment.  b Annexin V anti-
body binding, measured by flow cytome-
try, was significantly increased ( * p  ! 0.05; 
n = 9, HUVEC, 6 h after transfection) in 
cells where SHP-2 was knocked down 
(SHP-2 AS-ODN) compared to cells with 
normal levels of SHP-2 expression (Rdm-
ODN). 
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 Fig. 3. Inhibition of SHP-2 impairs the ability of endothelial cells 
to form capillary-like structures and vessel outgrowth in vivo. 
 a–d Representative photos of capillary-like structures (indicated 
by arrows, black bar in photos represents 200   m).  a HUVEC 
treated with sham solution.  b HUVEC treated with Rdm-ODN.
 c HUVEC treated with PtpI IV. d HUVEC treated with SHP-2 
AS-ODN.  e The ability to form capillary-like sproutings in Matri-
gel was significantly diminished when HUVEC were treated in 
separate experiments with either a specific inhibitor of SHP-2 
(PtpI IV, 2   M ) or SHP-2 AS-ODN compared to sham (DMSO)-
treated cells ( * p  ! 0.05; n = 3) or Rdm-ODN treatment, respec-
tively ( * * p  ! 0.01, n = 8). The structures were quantified 16 h fol-
lowing seeding of the cells.  f ,  g Representative photos of aortic 
rings 96 h following treatment showing the endothelial sprout-
ings (bifurcations are indicated by white arrows, bars in photos 
represents 200   m).  f Sham (DMSO) treatment.  g PtpI IV treat-
ment.  h The number of bifurcations on endothelial sproutings 
from mouse aortas was significantly lower upon SHP-2 inhibition 
( * p  ! 0.05, n = 8–10, PtpI IV). 
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ished following downregulation of the tyrosine phospha-
tase SHP-2 using the highly specific and effective magne-
tofection technique  [21] . As not only the cellular protein 
concentration but also the number of viable cells, mea-
sured by MTT reduction, were reduced after SHP-2 knock-
down, we hypothesized that SHP-2 is primarily important 
for the preservation of endothelial cell viability. This sug-
gestion was verified since staining the DNA of SHP-2 AS-
ODN-treated cells with propidium iodide resulted in a 
peak in SubG0, indicating enhanced cell death, which was 
not seen in Rdm-ODN transfected cells. We confirmed 
this inhibitory effect on apoptosis by annexin V staining, 
which also revealed a significantly higher amount of pro-
apoptotic cells following SHP-2 AS-ODN treatment, indi-
cating that SHP-2 is necessary for endothelial cell growth 
and survival. This is of major importance, since endothe-
lial cells loose their contact to the extracellular matrix, as 
the matrix is degraded during the initiation of the angio-
genic process to allow for new sprouting, without undergo-
ing apoptosis or anoikis. Thus, an anti-apoptotic role of 
SHP-2 in endothelial cells may be of significance for prop-
er angiogenesis to occur. These data are supported by stud-
ies where SHP-2 was shown to influence growth  [31] and 
EGF-stimulated cell cycle progression in fibroblasts  [32] .
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 Fig. 3.  i Vessel outgrowth in the CAM of chick embryos was se-
verely affected by SHP-2 inhibition ( * * p  ! 0.01, n = 4, PtpI IV). 
 j–l Representative sections of photos of vessel outgrowth in the 
chicken CAM 72 h (white bar = 500   m) following sham treat-
ment (DMSO;  j ), VEGF + FGF-2 (both 50 ng/ml) + DMSO treat-
ment ( k ) and VEGF + FGF-2 + PtpI IV treatment ( l ).  m The level 
of cytotoxicity of HMEC treated with PtpI IV (2   M ) compared 
to sham treatment (DMSO, v/v) was assessed by trypan blue ex-
clusion. PtpI IV treatment showed at no time an increase in non-
viable cells compared to sham treatment (n = 7).
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 Fig. 5. SHP-2 regulates FGF-2-dependent ERK activity through 
PI3-K in endothelial cells. HMEC  were stimulated with FGF-2
(10 ng/ml for 10 min), lysed and subjected to Western blotting.
 a ERK1/2 phosphorylation upon FGF-2 stimulation was prevent-
ed when SHP-2 was absent following SHP-2 AS-ODN treatment 
but not when Rdm-ODN was used (n = 5).  b Direct activation
of ERK1/2 by protein kinase C-dependent phosphorylation (by
1   M PMA) was not affected by SHP-2 knock-down (n = 3).
 c Whereas FGF-2 induced ERK1/2 phosphorylation, wortmannin 
treatment followed by FGF-2 stimulation (10 ng/ml) abrogated 
these effects (n = 3, HMEC). LCTRL = Loading control. 
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 Fig. 4. SHP-2 is needed for FGF-2 activation of the endothelial PI3-
K-Akt pathway. HMEC  were stimulated with FGF-2  (10 ng/ml for 
10 min), lysed and subjected to Western blotting.  a Whereas FGF-
2 stimulation caused an increase in tyrosine phosphorylation of 
the p85-regulatory subunit of PI3-K, SHP-2 AS-ODN transfection 
led to a decrease in FGF-2-dependent phosphorylation of p85
(n = 3) as assessed by immunoprecipitation of p85 and subsequent 
immunoblotting with an anti-pY antibody.  b Pharmacological 
SHP-2 inhibition (PtpI IV, 2   M ) also reduced the FGF-2-depen-
dent p85 phosphorylation (n = 4).  c Whereas FGF-2 stimulated 
Akt phosphorylation ( * p  ! 0.05, n = 10), knock-down of endothe-
lial SHP resulted in a loss of FGF-2-dependent Akt activation 
(anti-phospho-Akt immunoblotting, n = 4). Control = No stimu-
lation; LCTRL = loading control. 
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 The functional anti-angiogenic consequences of
SHP-2 inhibition are highlighted by the fact that knock-
down as well as pharmacological inhibition of SHP-2 im-
paired the ability of endothelial cells to form capillary-like 
structures in a proangiogenic assay. Furthermore, vessel 
sprouting ex vivo from mouse aortae was also severely af-
fected upon SHP-2 inhibition. Finally, inhibition of SHP-2 
resulted in impaired vessel growth in the chicken CAM 
strongly supporting the assumption that the positive role 
of SHP-2 on growth or anti-apoptotic pathways is a pre-
requisite for angiogenesis in vivo. Previous studies show-
ing a role for SHP-2 in cell motility by involving PECAM 
 [9] and focal adhesion kinase  [33] together with the obser-
vation that SHP-2-negative mutant endothelial cells failed 
to organize themselves into a highly vascularized network 
in the yolk sac of mouse embryos  [34] support our find-
ings that SHP-2 is an important angiogenic player.
 Since the MAPK pathway is known to be an eminent 
regulator of apoptosis  [35–37] and proliferation  [37] , pro-
cesses highly important for angiogenesis initiation, we 
next investigated if SHP-2 influences ERK1/2 activation 
in human endothelial cells. Indeed, stimulation with the 
angiogenic factor FGF-2 enhanced ERK1/2 activation, 
whereas deprivation of SHP-2 prevented this, indicating 
a role for SHP-2 in FGF-2-induced MAPK pathway acti-
vation and thus prevention of endothelial apoptosis. Since 
treatment with PMA, a direct stimulator of protein ki-
nase C, for 10 min has been shown to activate the Raf-
MEK (MAPK/ERK kinase)-ERK pathway independent 
of SHP-2 activation  [38] , we chose this approach to ensure 
that the effects of SHP-2 were specific and not an epiphe-
nomenon of cellular apoptosis. Activation of ERK1/2 
through PMA still enhanced ERK1/2 phosphorylation in 
spite of SHP-2 AS-ODN treatment demonstrating that 
the observed effects were not secondary to apoptosis. 
This coincides with previous findings where catalytically 
inactive SHP-2 inhibited FGF-induced ERK activation in 
 Xenopus embryos  [39] and where SHP-2 was required for 
sustained activation of MAPK by FGF in fibroblasts 
 [34] .
 In addition to the MAPK pathway, our findings sug-
gest that the PI3-K/Akt pathway, which is of major im-
portance for endothelial survival and cell cycle progres-
sion  [40, 41] , is equally involved in the protection from 
apoptosis by SHP-2, because FGF-2-dependent activation 
of PI3-K was also diminished after SHP-2 knock-down as 
well as upon pharmacological inhibition. These findings 
are supported by data showing a role for SHP-2 in IGF-1- 
and EGF-stimulated PI3-K activation and caspase-3-in-
duced apoptosis in fibroblasts  [42, 43] . Moreover, SHP-2 
AS-ODN treatment also reduced FGF-2-enhanced Akt 
phosphorylation in endothelial cells. Such central posi-
tion of SHP-2 in the regulation of endothelial cell viabil-
ity shifts the focus of the question towards the potential 
direct target of SHP-2 affecting these anti-apoptotic path-
ways. Others have reported that SHP-2 regulates ERK1/2 
activity through the Src kinase by promoting the disas-
sociation of the negative Src-regulator Csk  [44, 45] . In our 
study, however, treatment with wortmannin together 
with FGF-2 resulted in decreased ERK1/2 phosphoryla-
tion. This leads to the assumption that PI3-K does not 
only function to activate Akt, but also activates the MAPK 
pathway promoting endothelial cell survival and growth. 
Taken together these findings demonstrate that SHP-2 
regulates FGF-2-dependent ERK1/2 activation probably 
through PI3-K in human endothelial cells. Therefore, the 
regulatory subunit of PI3-K, p85, which is tyrosine phos-
SHP-2
SHP-2
FGF-2
p85
p110
Raf
MEK
ERK
Akt
Endothelial cell survival
and growth
New vessel formation
 Fig. 6. FGF-2-dependent SHP-2 signaling in endothelial cells. 
Upon FGF-2 stimulation, the p85 subunit of PI3-K becomes tyro-
sine phosphorylated, which renders the kinase active. This tyro-
sine phosphorylation is dependent on the presence of SHP-2. It is 
likely that SHP-2 and p85 are parts of the same signaling complex 
 [43] . SHP-2-dependent PI3-K activation leads to Akt and MAPK 
(Raf-MEK-ERK) pathway activation. This prevents apoptosis and 
stimulates growth, which are prerequisites for proper vessel for-
mation. These events were shown to be influenced by SHP-2 in this 
study. 
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 Thus our findings identify SHP-2 as a possible central 
regulating enzyme in endothelial cell signaling and an-
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sary for angiogenesis initiation by prevention of endothe-
lial cell apoptosis. SHP-2 may therefore be of interest in 
the development of treatment strategies involving angio-
genesis, as it may either be therapeutically prevented, 
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